Friday, September 18, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
MarketAllergan Publishes GLP-1 Skin Quality Data—Face Aging Reversal AngletodayDevices & TechInMode Launches Morpheus8 Cool on Morpheus8MAX2 days agoInjectablesTwo New Fillers Receive FDA Approval for Cheeks and LipstodayInjectablesMerz Expands Belotero With Volume and Intense Fillers2 days agoInjectablesGalderma's Restylane Volyme Clears China Temple Study—Regional Expansion AcceleratestodayBusiness & M&AInMode Takeover Bid Expires—Stock Pressure Mounts2 days agoBusiness & M&AInMode Takeover Bid Lapses—Stock Faces Pressure Without DealtodayInjectablesGalderma's Restylane Volyme Wins China Temple Study2 days agoInjectablesMerz Adds Two New Belotero Fillers—What's in the Portfolio NowyesterdayMarketGLP-1 Boom Opens Multi-Billion Aesthetic Play—Practices Repositioning NowyesterdayInjectablesFDA Updates Kybella Labeling—New Clinical Data Strengthens PositionyesterdayComplianceCPOM Crackdown Forces Med Spa MSO Restructuring—Deal Execution Tightensyesterday
Market

Allergan Publishes GLP-1 Skin Quality Data—Face Aging Reversal Angle

Allergan Aesthetics released clinical findings on skin changes in patients using weight-loss medications, positioning aesthetics practices to capture GLP-1 user demand.

Image: Inside MedSpa
By at Inside MedSpa · Sep 18, 2026
1-YEAR MOVE
+15% −13%
ABBV ▲11.6%
1-year price move by ticker
TickerCompany1-year change
ABBVAbbVie (Allergan Aesthetics)+11.6%

Allergan Aesthetics presented clinical data evaluating skin quality improvements in individuals on medical weight-loss medications—a direct play on the GLP-1 user demographic that's already reshaping practice economics. The study captures what anecdotal reports have suggested: patients on semaglutide and tirzepatide report visible facial rejuvenation, with some describing a 10-year younger appearance.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Patients on weight-loss drugs reported faces looked about 10 years younger, backed by clinical study.

This is Allergan's move to anchor aesthetic practices in the GLP-1 conversation. The data gives practices a clinical foundation to market injectables and skin treatments to an expanding patient cohort that's simultaneously losing weight and seeking facial restoration. The timing matters: as GLP-1 adoption accelerates, the collateral demand for filler, neuromodulator, and skin quality treatments will follow. Allergan is positioning Botox and Restylane as the clinical complement to weight loss, not the alternative.

Source: original report ↗

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://insidemedspa.com/article/allergan-glp1-skin-quality-clinical-data/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa Pro

    By the time it's news, it's too late.

    The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

    Get the free brief Never miss a recall or a rule change. Cancel anytime.
    The twice-a-week intelligence brief Get the free brief →